Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4144 in obesity
NCT06942923Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing AZD4144 with Placebo (2 arms). Primary endpoints: Adverse Events at 8 weeks and Interleukin-6 at 4 weeks. Started Apr 2025; status: completed.
02
Drugs
AZD4144
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06942923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942923.